https://www.selleckchem.com/pr....oducts/gw-441756.htm
In a large series of White patients with refractory uveitis due to Behçet disease (BD) being treated with infliximab (IFX), we assessed (1) long-term efficacy and safety of IFX, and (2) IFX optimization when ocular remission was achieved. Our multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressant agents treated 103 patients/185 affected eyes with IFX as first biologic therapy in the following intervals 3-5 mg/kg intravenous at 0, 2, 6, and then every 4-8 weeks. The main outcome variables